Hepatitis B Immune Globulin Cangene

HepaGam B® [Hepatitis B Immune Globulin (Human) Injection] contains purified antibodies specific for the hepatitis B surface antigen (HBsAg). * It is approved in Canada and the United States f...

Glybera

uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused...

Salmonella newport

Salmonella in humans Salmonella bacteria cause food poisioning, typhoid fever and paratyphoid fever. More than 2500 different strains of salmonella have been identified.  Anyone can get salmo...

NanoBio CEO leaves to head Merck vaccine franchise

NanoBio Corp. (Ann Arbor, Mich.) said founder and CEO James Baker left to join Merck & Co. Inc. (NYSE:MRK) as SVP, head global vaccine franchise. NanoBio promoted David Peralta to CEO from COO and CFO...

Editorial: Nanobio versus Bionano – what's in a name?

Nanobio versus Bionano – what's in a name?This special Issue of Biotechnology Journal includes two sections, one featuring articles on nanobio, the other articles on bionano. The editors of the issu...

NanoBio-Europe conference to take place from June 18-20 in Varese

The 8th NanoBio-Europe conference will take place on 18 - 20 June 2012 in Varese (Lombardy, Northern Italy), showcasing the latest international developments in nanobiotechnology, and providing a plat...

So Close They Can Taste It; NanoBio, Investors Eye Potential IPO

Is NanoBio heading towards an IPO? Probably way too early to make that call. But the Ann Arbor, MI-based drug startup and its investors are not exactly discouraging such talk. “I think the compa...

NanoBio Announces Data Presentation on its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012

ANN ARBOR, Mich. & SAN DIEGO--(BUSINESS WIRE)--Oct 15, 2012 - NanoBio® Corporation announced today that results from its nanoemulsion adjuvanted RSV vaccine will be presented at IDWeek 2012&...

NanoBio to Present Preclinical Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine and Novel Inhaled Cystic Fibrosis Therapy at 52nd Annual ICAAC Meeting

ANN ARBOR, Mich.--(BUSINESS WIRE)--September 10, 2012 10:48 AM Eastern Daylight Time--NanoBio® Corporation announced today it will present data from two separate preclinical studies at the 52nd In...

NanoBio to Report Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine at the 8th Annual International Respiratory Syncytial Virus Symposium

ANN ARBOR, Mich. & SANTA FE, N.M.--(BUSINESS WIRE)--Sep 24, 2012 - NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Re...

Series C from returning shareholders brings $11mm to [NanoBio]

[NanoBio Corp.] (vaccines, dermatological agents, and anti-infectives) has raised $11mm in its Series C financing from all returning shareholders including Perseus LLC and Venture Investors. Funds wil...

Evolution of clinical trials registries.

Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice.

PURPOSE Many phase III trials presented at annual meetings of the American Society of Clinical Oncology (ASCO) remain unpublished. The results of these unpublished trials, if more generally known, mig...

Setting up a Respiratory Trials Unit.

Clinical trials are an essential in advancing our knowledge and treatment of patients with respiratory disease. Conducting well designed clinical studies which accurately and reliably answer important...

Spinal cord clinical trials and the role for bioengineering.

There is considerable need for bringing effective therapies for spinal cord injury (SCI) to the clinic. Excellent medical and surgical management has mitigated poor prognoses after SCI; however, few a...

NHLBI clinical trials workshop: an executive summary.

On September 13-14, 2010, the National Heart, Lung and Blood Institute (NHLBI) organized a workshop: 'Clinical Trials: Past, Present and Future'. The workshop covered many areas in clinical trials, in...